| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 103.69 | 5.8% | 29.2% |
| Total Income | 103.69 | 5.8% | 29.2% |
| Expenditure | 110.86 | 1.8% | 24.9% |
| PBT | 0.30 | 103.1% | 95.1% |
| Net Profit | -0.18 | 98.3% | 102.1% |
| OPM | -6.92% | 8.27pp | 3.68pp |
| NPM | -0.17% | 10.34pp | 11.06pp |
| EPS | 0.00 | 100.0% | 100.0% |
Immunocore Reports Q3 2025 Revenue of $103.7 Million, Up 29% YoY
04 May 2026 · 4 May, 7:45 am
Summary
Immunocore Holdings plc announced its financial results for the third quarter ended September 30, 2025. KIMMTRAK net product sales were $103.7 million for the quarter, representing a 29% increase year-over-year. For the nine months ended September 30, 2025, KIMMTRAK net product sales were $295.5 million, up 31% compared to the same period in 2024. The company's cash, cash equivalents, and marketable securities amounted to $892 million as of September 30, 2025. The Phase 3 TEBE-AM trial is expected to complete enrollment in the first half of 2026.
Key Highlights
- 1
KIMMTRAK® net revenues reached $103.7 million in Q3 2025, reflecting a 29% year-over-year growth.
- 2
For the nine months ended September 30, 2025, KIMMTRAK net product sales were $295.5 million, a 31% increase compared to the same period in 2024.
- 3
The Phase 3 TEBE-AM trial is on track to complete enrollment in the first half of 2026.
- 4
The company's cash, cash equivalents, and marketable securities totaled $892 million as of September 30, 2025.
- 5
160 mcg was selected as the go-forward dose for brenetafusp in the Phase 3 PRISM-MEL-301 trial, following an Independent Data Monitoring Committee review.
Management Comments
Bahija Jallal
Our commercial momentum continues with over $100 million in sales this quarter and enables sustained investment in innovation. We are executing to plan – advancing three Phase 3 melanoma trials and multiple mid‑stage programs – to deliver transformative outcomes for patients and sustained value for shareholders.”
Informational and educational content only. Not investment advice.